Inactive Instrument

Other languages Celladon Corp Nasdaq

Equities

US15117E1073

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors	Apr. 03
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01
Top Midday Decliners	Apr. 01
Sector Update: Health Care	Apr. 01
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	Apr. 01
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.	Apr. 01
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy	Apr. 01
Eiger BioPharmaceuticals, Inc. Announces Christine A. Murray Notifies Resignation as Member of Board of Directors, Effective March 15, 2024	Mar. 11
Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024	Jan. 24
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	Jan. 19
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 18
Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals	Nov. 24
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Eiger to discontinue hepatitis drug study over safety concerns	23-09-12
Eiger to discontinue hepatitis drug study	23-09-12
Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta	23-09-12
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Eiger BioPharmaceuticals Names David Apelian Permanent Chief Executive; Cuts Workforce by 25%	23-06-29
Eiger Biopharmaceuticals, Inc. Appoints David Apelian, as CEO	23-06-29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Celladon Corp Nasdaq

Equities

US15117E1073

Other languages

Filters